Lantheus (LNTH) Projected to Post Quarterly Earnings on Wednesday

Lantheus (NASDAQ:LNTH - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $389.69 million for the quarter. Lantheus has set its FY 2025 guidance at 6.600-6.700 EPS.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. The firm's revenue was up .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.69 EPS. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded up $2.00 during midday trading on Friday, hitting $72.93. The company's stock had a trading volume of 615,452 shares, compared to its average volume of 1,083,256. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The stock's 50 day simple moving average is $78.06 and its 200 day simple moving average is $88.72. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of 20.72 and a beta of 0.12. Lantheus has a fifty-two week low of $69.12 and a fifty-two week high of $118.21.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LNTH. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley lowered their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Finally, Truist Financial reduced their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $131.20.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.